-
Best Pet Advent Calendars for Christmas 2026: Dog Treats and Cat Toys
-
IIM Indore Announces IPMAT 2027 Exam Date for April 24
-
Grattan Institute Releases Blueprint to Target Specialists Over Excessive Fees
-
The Dilemma of Recording Live Music: Preserving Memories vs. Being Present
-
Arizona Science Center Hosts Girls in STEM Astro Adventures for Students
-
ANC’s Renewal Rhetoric Fades as Voters Reject Party in 2026 Local Elections
-
New Turkish Cafe, Japanese BBQ, and Korean Restaurants Open Across East Bay
-
Foreign Investors Return to Indian Markets After 10-Month Selloff
-
Knowle Move Four Points Clear at Top After Histon Victory
-
Honda CR-V and Toyota RAV4 Lead Canada’s Most Stolen Vehicles List for 2025
-
Physicians Urge Arizona to Ban Medical Gag Clauses and Enable Private Lawsuits
-
China Extends Tariff Suspension on US Imports to Stabilize Trade Ties
-
New Campaign Highlights Knowledge Gaps on Carbon Monoxide Safety Among Americans
-
JR East Launches 'teppay' to Integrate Suica Balance with Mobile Payments
Bayer sets aside more cash to deal with weedkiller woes
German pharmaceutical and agricultural chemicals giant Bayer said it had put aside an extra 1.2 billion euros ($1.4 billion) to deal with long-running US legal woes linked to a weedkiller.
It takes to 1.7 billion euros the amount set aside to deal with litigation linked to the glyphosate-based Roundup weedkiller, the German group said in a statement late Thursday.
Bayer also said it had achieved a "major settlement" with a law firm "reducing the total number of unresolved glyphosate claims to 61,000".
This means that a total of 131,000 claims had so far either been settled or deemed not eligible, it said.
The flood of legal cases in the United States relates to claims that the weedkiller causes blood cancer. Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.
The Leverkusen-based group has already spent over $10 billion to settle cases.
Despite the extra provision for the legal cases, Bayer hiked its forecasts for 2025 due to a better-than-expected performance in its pharmaceuticals division.
The maker of Aspirin now expects sales of 46 to 48 billion euros this year up from a previous forecast of 45 to 47 billion.
It also predicted earnings before interest, taxes, depreciation and amortisation -- a key measure of profitability -- of 9.7 to 10.2 billion euros up from a previous forecast of 9.5 to 10 billion.
Its shares were up two percent on the blue-chip DAX index in Frankfurt Friday, while the broader index slipped 1.8 percent.
X.Brito--PC